MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and ...

MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

The cancer can cause 'referred pain' - where you feel discomfort in one area even though the source of the pain is elsewhere ...

The following is a summary of “A Review of Nonsurgical Neurolytic Procedures for Neuropathic Pain,” published in the February ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Adults with neuropathic pain use cannabis products more frequently than those without neuropathic pain. | Cannabis Sciences ...

For executives of Lexicon Pharmaceuticals Inc., the missed primary endpoint in the phase IIb Progress study testing pilavapadin, its non-opioid candidate, in adults with moderate to severe diabetic ...

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

To manage the daily pain, frequent brain fog, and sporadic days of full-body exhaustion, my primary care doctor suggested a ...